Management of Dengue Fever
For patients with suspected or confirmed dengue fever, management is primarily supportive with careful fluid management tailored to disease severity—most patients (>90%) can be managed as outpatients with oral hydration and close monitoring, while those with warning signs or shock require hospitalization with judicious intravenous fluid resuscitation starting at 20 mL/kg boluses. 1, 2
Risk Stratification and Triage
Dengue follows a characteristic triphasic course: febrile phase (days 1-3), critical phase (days 4-7 when plasma leakage occurs), and recovery phase (after day 7) 2. The key to management is identifying which patients require hospitalization versus outpatient monitoring.
Hospitalize patients with:
- Warning signs: Abdominal pain, persistent vomiting, clinical fluid accumulation (ascites, pleural effusion), mucosal bleeding, lethargy/restlessness, liver enlargement >2 cm, rising hematocrit with rapid platelet decline 3
- Severe dengue: Plasma leakage leading to shock, severe bleeding, or organ impairment 2
- High-risk comorbidities: Pregnancy, infancy, elderly, diabetes, cardiovascular disease 2
Outpatient management is appropriate for:
- Uncomplicated dengue without warning signs
- Ability to maintain oral hydration
- Reliable access to medical care for daily monitoring 3, 4
Diagnostic Approach
Early illness (days 1-5): Use RT-PCR or NS1 antigen detection for confirmation 1, 5
Later illness (≥5-7 days): IgM antibody testing becomes reliable, though cross-reactivity with other flaviviruses (Zika, West Nile, yellow fever) can occur 5
Serial monitoring parameters:
- Complete blood count with hematocrit every 12-24 hours during critical phase
- Platelet count (though thrombocytopenia alone does not mandate admission—14% of patients had platelets <20,000/µL without bleeding) 4
- Liver enzymes if clinically indicated
- Point-of-care ultrasound for early detection of plasma leakage (gallbladder wall thickening, ascites, pleural effusions) 6
Fluid Management Strategy
Outpatient Management
Oral rehydration with 1.5-2 L/day of oral fluids containing electrolytes 3. Patients should be monitored daily during the critical phase with instructions to return immediately if warning signs develop.
Inpatient Management Without Shock
For patients with warning signs but no shock, start crystalloid fluids at maintenance rates (typically 1.5-2 mL/kg/hour for adults) 3. Monitor hematocrit every 6-12 hours:
- If hematocrit stable or decreasing: Continue maintenance fluids
- If hematocrit rising: Increase to 2-4 mL/kg/hour for 2-4 hours, then reassess 3
Critical pitfall: Avoid fluid overload, which can lead to pulmonary edema and respiratory distress. The Japanese experience showed effective management with volumes substantially lower than WHO recommendations—median 1500 mL in first 24 hours for non-severe disease without warning signs 7.
Management of Dengue Shock Syndrome
Initial resuscitation: Administer 20 mL/kg crystalloid bolus over 15-30 minutes 8, 9, 10. Reassess immediately after each bolus.
Fluid choice: Use crystalloids (normal saline or Ringer's lactate) as first-line. Colloids may be considered in children with severe dengue shock syndrome (pulse pressure <10 mmHg) but offer no advantage in moderate shock 8. Given cost and potential adverse effects, crystalloids remain preferred in most settings 8.
Endpoints of resuscitation (assess after each bolus):
- Systolic blood pressure ≥90 mmHg in adults
- Normal capillary refill time (<2-3 seconds)
- Warm extremities with palpable peripheral pulses
- Urine output >0.5 mL/kg/hour in adults, >1 mL/kg/hour in children
- Improved mental status
- Absence of skin mottling 8
If shock persists despite 40-60 mL/kg fluid resuscitation: Start vasopressors—dopamine or epinephrine 8. Monitor blood pressure and heart rate frequently. Consider hydrocortisone up to 300 mg/day in adults requiring escalating vasopressor doses 8.
Aggressive fluid resuscitation may require >4 L in first 24 hours for adults, but continue reassessing for fluid overload 8. The critical phase typically lasts 24-48 hours 8.
Supportive Care
Antipyretics: Use acetaminophen/paracetamol only—avoid NSAIDs and aspirin due to bleeding risk and potential for Reye's syndrome 2
Transfusion thresholds:
- Platelet transfusion only for active bleeding with severe thrombocytopenia, not based on platelet count alone 4
- Packed red blood cells for significant hemorrhage with hemodynamic compromise 2
Monitoring position: Semi-recumbent position (head elevated 30-45°) for conscious patients; lateral position for unconscious patients with airway maintenance 8
Oxygen therapy: Target oxygen saturation >90% 8
Key Clinical Pitfalls
Over-reliance on platelet counts: 87.4% of patients had uncomplicated dengue despite thrombocytopenia; 14% had platelets <20,000/µL without bleeding 4. Hospitalization decisions should be based on warning signs and clinical status, not platelet count alone.
Excessive fluid administration: Fluid overload causes more harm than benefit in patients without shock. Japanese data showed excellent outcomes with conservative fluid volumes 7.
Fever persistence misinterpretation: 28% of patients remained afebrile for >72 hours despite declining platelets—fever resolution is independent of thrombocytopenia and doesn't indicate recovery 4.
Missing the critical phase: Days 4-7 are when plasma leakage and shock develop. This is when intensive monitoring is essential, even if the patient appears to be improving 2.
Antimicrobial use: Dengue is viral—do not administer antibiotics unless bacterial co-infection is documented 8. The evidence on sepsis management applies only when bacterial infection is confirmed, not for dengue fever itself.
No Specific Antiviral Therapy
There is no treatment directed against dengue virus—management is entirely supportive 2. The focus is preventing progression to severe disease through appropriate fluid management and early recognition of deterioration.